MILESTONE SCIENTIFIC INC.
Milestone Scientific develops and sells dental and medical instruments and related single-use disposable handpieces. Its business includes dental and medical sales, with dental products accounting for most sales and medical products forming a smaller part of its business. The company’s product development includes the Single Tooth Anesthesia System instrument and a medical product platform. Milestone Scientific makes money primarily by selling instruments and disposable handpieces to customers, including through international dental sales and domestic medical handpiece sales. Instrument revenue is generally recognized upon shipment or delivery, depending on contractual terms, while disposable handpiece revenue is recognized when control transfers to the customer. The company is based in Livingston, New Jersey.
No SEC Form 4 filings for $MLSS in the last 30 days.
See all $MLSS insider activity →Milestone Scientific (MLSS) reported Q3 revenue of $2.2M, down 5.9% YoY, with a net loss of $748K. The company reaffirmed its 2026 revenue outlook of $9.8M–$10.2M and expects to approach profitability in Q4 2026, according to the company.
Milestone Scientific Inc. (MLSS) converted $465,000 in debt to 976,870 shares of common stock at $0.50 per share, eliminating its debt. The conversion was done by three board members and completed on August 19, 2026. MLSS is trading at $0.49, up 2.87%.
Milestone Scientific (MLSS) reported Q2 2026 revenue of $2.8 million, up 22% year over year, and $5.0 million for the first six months, up 10%. CompuFlo medical revenue rose 230% and the company entered a distribution agreement with Red One Medical for VA and DoD systems. It reaffirmed 2026 double-digit revenue growth outlook.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning MLSS (MILESTONE SCIENTIFIC INC.). Coverage has been balanced: 2 bullish, 3 neutral, and 2 bearish.
Recent MLSS coverage spans earnings, corporate actions and financial news.
Mixed results: revenue decline may weigh on the stock, but narrowing losses and steady guidance could limit downside.
Debt elimination improves balance sheet but dilutes existing shareholders; modest price impact expected.
Near-term sentiment likely hinges on medical segment momentum (CompuFlo growth, reimbursement progress) and whether the new federal distribution deal accelerates sales.
Board committee leadership changes and director re-elections are unlikely to drive near-term fundamentals, but can affect governance and oversight focus.
The release is a product commercialization step, but it provides no financial targets or adoption metrics, limiting near-term earnings impact visibility.
AlphAI scores every news story that mentions MLSS with an AI model for sentiment and relevance, and aggregates insider trades from MILESTONE SCIENTIFIC INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Milestone Scientific (MLSS) reported Q3 revenue of $2.2M, down 5.9% YoY, with a net loss of $748K. The company reaffirmed its 2026 revenue outlook of $9.8M–$10.2M and expects to approach profitability in Q4 2026, according to the company.
Milestone Scientific Inc. (MLSS) converted $465,000 in debt to 976,870 shares of common stock at $0.50 per share, eliminating its debt. The conversion was done by three board members and completed on August 19, 2026. MLSS is trading at $0.49, up 2.87%.
Milestone Scientific (MLSS) reported Q2 2026 revenue of $2.8 million, up 22% year over year, and $5.0 million for the first six months, up 10%. CompuFlo medical revenue rose 230% and the company entered a distribution agreement with Red One Medical for VA and DoD systems. It reaffirmed 2026 double-digit revenue growth outlook.
MILESTONE SCIENTIFIC INC. (MLSS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Ms. Kelly Ulto and Mr. Greg Shilling were elected by the Board of Directors (the “Board”) of Milestone Scientific Inc. (the
Milestone Scientific Inc. (NYSE American: MLSS) said it launched the first phase of its AI strategy at ASPN 2026 in Miami Beach, debuting Milo, an AI-enabled digital engagement platform. The pilot will answer product questions, provide education, collect customer info, support lead qualification, and help schedule demos. The company plans to use attendee feedback to guide further development.
Milestone Scientific (NYSE: MLSS) reported preliminary, unaudited revenue for Q2 2026 of about $2.8M (+21% YoY) and 1H 2026 of about $5.0M (+9% YoY). The company expects medical-segment revenue up 300% YoY in Q2 and cites international order upside, plus reimbursement claims and conference plans in July.
MILESTONE SCIENTIFIC INC. (MLSS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.3 4 ex10-3.htm EX-10.3 Exhibit 10.3 As of June 19, 2026 Benedetta Casamento 346 Hillcrest Road Englewood, NJ 07631 Dear Benedetta: On behalf of the Board of Directors of Milestone Scientific Inc. (the “ Company ”), I am pleased to confirm your appointment as Executive Chair
Milestone Scientific (MLSS) reported a narrowed net loss of $0.84 million in Q1 2026, primarily due to sharply reduced operating expenses and a pause in R&D. Despite this improvement and positive operating cash flow, the company faces substantial doubt about its ability to continue as a going concern, evidenced by an accumulated deficit of $134.6 million and limited cash reserves. Additionally, MLSS remains below NYSE American listing thresholds, with a compliance deadline of April 2027, and its recent $2.15 million private placement introduced further dilution risks for existing shareholders.
Milestone Scientific Inc. (MLSS) has appointed Grassi & Co., CPAs, P.C. as its new independent registered public accounting firm, effective for the fiscal year ending December 31, 2026. This follows the dismissal of CBIZ CPAs P.C. as their auditor, a change approved by the company's Board of Directors. The previous auditor's report for 2025 indicated substantial doubt about Milestone Scientific's ability to continue as a going concern, though no disagreements on accounting principles or audit scope were reported.
Milestone Scientific Inc. ( NYSE:MLSS ) shares surged 35.67% in after-hours trading on Thursday, rising to $0.52. The medical device firm reported its third-quarter results showing lower costs and improved losses. Check out the current price of MLSS stock here.
